-
View from the Trenches: Panel reviews practice-changing presentations from SABCS 2022
On Friday, December 9, experts highlighted the updates from SABCS 2022 that may have an immediate impact for patients and physicians.
-
Year in Review session summarizes important developments in breast cancer
Andrei Goga, MD, PhD; Shom Goel, MBBS; Marleen Kok, MD, PhD; and Melinda Telli, MD, outlined updates across the spectrum of breast cancer research and clinical practice on Saturday, December 10.
-
Panelists examine key clinical controversies in breast cancer
Viviana Galimberti, MD, and fellow panelists explored evolving questions around the utility of targeted axillary dissection, the optimal duration of endocrine therapy, and the role of neoadjuvant therapy in triple negative breast cancer during a session Wednesday, December 7.
-
Experts debate current controversies in translational medicine
Hope S. Rugo, MD, opened a discussion session on Thursday, December 8, which explored different opinions on the future of minimum tolerable dose (MTD), randomized trials vs. real-world evidence, and the utility of Ki67 as a clinical biomarker.
-
AACR distinguished lecturer delves into prognosis potential of genomic subtypes of breast cancer
Charles M. Perou, PhD, spoke Wednesday, December 7, about the importance of quantitative and objective means for measuring the intrinsic subtypes and immune signatures of breast cancer.
-
General Session 4 includes latest results from Alliance, POLAR, POSITIVE studies
The fourth General Session featured data from trials on breast-conserving therapy and local recurrence, short-term recurrence rates in patients who pause endocrine therapy to pursue pregnancy, and more.
-
General Session 5 features novel approaches to CNS metastases
The fifth General Session included data from two preclinical studies suggesting new approaches to both treating and identifying brain metastases in triple negative and inflammatory breast cancer.
